PD-L1 Targeting Molecular Imaging of Solid Tumors

Recruiting N/A Interventional Study
Gastrointestinal Tumors
No Placebo Group Every participant receives an active treatment — no one gets a placebo.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 and older
Sex
Any
Study type
Interventional
Purpose
Diagnostic
Participants needed
20 (estimated)
Sponsor
Peking University Cancer Hospital & Institute · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial

The objective of the study is to constrcut a noninvasive approach WL12 PET/CT to detect the PD-L1 expression of tumor lesions in patients with gastrointestinal tumors and to identify patients benefiting from anti-PD-1/L1 treatment.

Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * 1\. Aged \>18 years old; ECOG 0 or 1; * 2\. Patients with Gastrointestinal tumors; * 3\. Has at least one measurable target lesion according to Response Evaluation Criteria in Solid Tumors (RECIST V1.1); * 4\. life expectancy \>=12 weeks. Exclusion Criteria: * 1\. Significan…
Contacts

Hua Zhu

010-88196495

zhuhuabch@pku.edu.cn

CONTACT